Marta Alonso, Universidad de Navarra, Spain
M. Alonso develops therapies based on oncolytic adenoviruses to treat pediatric brain tumors. Her group uses novel and relevant in vitro and in vivo models of pediatric brain tumors and sarcomas, with the intention of implementing these strategies in children with brain tumors.
Hildegund Ertl. The Wistar Institute, Philadelphia, PA, USA
H. Ertl’s research centers on developing vaccines for an array of diseases and conditions, including AIDS and some forms of cancer. Among other strategies, her group uses non-human adenoviruses as vectors to boost the vaccine efficacy.
Walter F. Mangel, Brookhaven National Laboratory, Upton, NY, USA
Work by the group lead by W. F. Mangel has produced a detailed description of the one-dimensional chemistry mechanism used by the adenovirus protease to produce the mature particle. They are also interested in the properties of the protease as an antiviral target.
Harald Wodrich, Laboratoire de Microbiologie Fondamentale et Pathogénicité, University of Bordeaux, France
The group led by H. Wodrich develops in vivo imaging approaches to study the spatio-temporal organization of relevant host-pathogen interactions in living cells. They apply these methods to understand how adenovirus genomes traffic in the host cell, from entry to replication and assembly